Previous 10 |
Forte Biosciences (NASDAQ: FBRX ) : Q2 GAAP EPS of -$9.52. More news on: Forte Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the second quarter 2020 financial results and provided a general business update. “We are very happy to have concluded the reverse merger on June 15 th and in...
Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today that it will release second quarter 2020 results after the market close on Monday, August 10, 2020 and host a conference call at 4:30 p.m. ET to discuss second quarter 20...
News, Short Squeeze, Breakout and More Instantly...
Forte Biosciences Inc. Company Name:
FBRX Stock Symbol:
NASDAQ Market:
Forte Biosciences Inc. Website:
Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced first quarter 2024 results and provided a business update. First Quarter 2024 Business Highlights ȁ...
Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its 2023 results and provided a business update. 2023 Business Highlights “Forte achieved a major...